Ultima Genomics and BaseClear to expand european access to low-cost and high-throughput sequencing using Ultima's UG200 Platform. Jul 29, 2026, 08:00 ET BaseClear will become the first Ultima Certified Service Provider in Europe and offer sequencing services on the UG200 Platform that unlock a new level of scale and economics for a wide range of data-intensive applications Builds upon BaseClear's selection as the commercial service provider for Basecamp Research's AI-scale Trillion-Gene Atlas to be run on Ultima's UG200 Platform FREMONT, Calif. and LEIDEN, the Netherlands, July 29, 2026 /PRNewswire/ - Ultima Genomics and BaseClear B.V., a Netherlands-based genomics services provider, today announced that BaseClear will adopt Ultima's UG200 Platform and launch sequencing services offering transformative economics and scale for customers across Europe and globally. BaseClear's deep expertise in genomics, lab automation and bioinformatics, combined with Ultima's scalable sequencing architecture and UG200 Platform, provides a compelling offering for data-intensive applications. BaseClear will offer an automated workflow from sample receipt to genomic extraction, library prep, sequencing and data delivery for clients, powered by Ultima's platform. This offering provides researchers, Cell & Gene Therapy, Vaccine, and Industrial Biotechnology customers with access to scalable, cost-effective data generation for biomarker discovery, clinical research and pharmacogenomic studies, enzyme discovery, large-scale transcriptomics, single-cell analysis, germline and somatic whole-genome sequencing, metagenomics, and other sequencing-intensive applications. This follows BaseClear's selection by Basecamp Research as the service provider to support its efforts to build a Trillion Gene Atlas, an initiative designed to generate and model biological data at trillion-gene scale. BaseClear will use Ultima's UG200 Sequencing Platform to support Basecamp Research's initiative and will expand access to Ultima's technology to meet the growing need for sequencing technologies and services infrastructure for AI-scale biological data generation. "Large-scale biological discovery increasingly depends on the ability to generate high-quality genomic data at an unprecedented scale," said Gilad Almogy of Ultima Genomics. "BaseClear's scientific expertise, services infrastructure and vision to support ever larger scale initiatives make them an important partner as we expand access to Ultima-enabled sequencing. Together, we can help more customers pursue ambitious genomics programs with the scale, throughput and economics these projects require." "BaseClear's priority is helping customers access the sequencing technologies and scientific support needed to answer complex biological questions," said Roel Sterken, CEO of BaseClear. "Ultima's UG200 Platform has established a new benchmark for scale and economics. By adding Ultima's platform to our sequencing services portfolio, we can offer customers a powerful new option for projects where scale, data integrity and cost efficiency are critical. This enables organizations to make faster and better data-driven decisions, ultimately helping innovative therapies reach patients faster while saving costs. We look forward to working with Ultima to support customers across a range of high-throughput applications." BaseClear launched its Ultima-enabled services in mid-July 2026, with additional information available at https://www.baseclear.com/technology/ultima-high-throughput-sequencing/. About Ultima Genomics Ultima Genomics is unleashing the power of genomics at scale. The Company's mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. With humanity on the cusp of a biological revolution, there is a virtually endless need for more genomic information to address biology's complexity and dynamic change - and a further need to challenge conventional next-generation sequencing technologies. Ultima's revolutionary new sequencing architecture drives down the costs of sequencing to help overcome the tradeoffs that scientists and clinicians are forced to make between the breadth, depth and frequency with which they use genomic information. The new sequencing architecture was designed to scale far beyond conventional sequencing technologies, lower the cost of genomic information, and catalyze the next phase of genomics in the 21st century. To learn more, visit www.ultimagenomics.com. About BaseClear BaseClear B.V. is a Netherlands-based genomics service company with more than 30 years of experience supporting innovations and products that advance human and animal health, enable food safety, product integrity and promote a sustainable future. BaseClear offers a complete range of genomic services, including next-generation sequencing, Sanger sequencing, qPCR and dPCR assays, bioinformatics and regulatory consulting under an umbrella of ISO17025, ISO27001 and GMP-compliant quality standards. From project design through post-market launch, BaseClear supports customers with state-of-the-art laboratory capabilities, expert project management and comprehensive reporting and interpretation. To learn more, visit www.baseclear.com. Media Contact Vikki Herrera Oak Street Communications for Ultima Genomics [email protected] 408-206-7009 SOURCE Ultima Genomics

Anthropic launches Claude Science workbench for drug discovery and biotech research. Key points * Claude Science is an AI workbench for scientists with 60-plus pre-configured skills spanning genomics, proteomics, structural biology, and cheminformatics - not a new AI model [[1]] * The product launched in beta for Claude Pro, Max, Team, and Enterprise users, with native integration of NVIDIA BioNeMo models including Evo 2, Boltz-2, and OpenFold3 [[1]] * Anthropic is funding up to 50 research projects with $30,000 in credits each, with applications open through July 15 [[1]] * Bristol Myers Squibb, which signed a separate enterprise deal in May deploying Claude across 30,000-plus employees, joined Novartis and Genentech CEOs on stage at the launch event [[3]] [[4]] * UCSF researcher Stephen Francis reported the platform completed germline workups in roughly one-tenth the previous time [[1]] Anthropic on June 30 launched Claude Science, an AI workbench that consolidates more than 60 scientific databases and computational tools into a single research environment for life-science researchers. The product debuted in beta at a San Francisco event called "The Briefing: AI for Science" at the Yerba Buena Center, where CEO Dario Amodei appeared alongside the heads of three major pharmaceutical companies [[1]] [[2]]. Claude Science is not a new foundation model. It runs on Anthropic's existing Claude architecture, including Claude Opus 4.8, and instead layers a coordinating agent with over 60 curated skills and connectors pre-configured for genomics, single-cell analysis, proteomics, structural biology, and cheminformatics. The platform natively renders 3D protein structures, genome browser tracks, and chemical structures, and integrates with NVIDIA's BioNeMo toolkit including models such as Evo 2, Boltz-2, and OpenFold3 [[1]]. The launch event featured a panel including Bristol Myers Squibb CEO Chris Boerner, Novartis CEO Vas Narasimhan, Genentech executive vice president Aviv Regev, and GLP-1 drug inventor Lotte Knudsen, signaling the depth of pharma industry engagement with the product [[2]] [[3]]. Anthropic simultaneously announced a grant program offering up to $30,000 in compute credits per project for up to 50 research teams, with applications open through July 15 [[1]]. Discover more AI intelligence platform Urban & Regional Planning AI market intelligence How it works. Claude Science operates as a customizable workbench that connects to more than 60 scientific databases - including UniProt, the Protein Data Bank, Ensembl, Reactome, ClinVar, ChEMBL, and Gene Expression Omnibus - through a generalist coordinating agent. Specialist agents handle domain-specific tasks, while a built-in reviewer agent flags citation errors and calculation inconsistencies [[1]]. The platform runs locally on macOS or Linux, or remotely via SSH or HPC login nodes. It manages job submission to a user's high-performance computing cluster or to Modal for on-demand GPU access, scaling from a single GPU to hundreds as needed. Every output carries an auditable history for validation and reproducibility [[1]]. Anthropic also integrated Basecamp Research's EDEN biological dataset, which contains sequencing data from millions of microbe species, giving researchers access to a broad genomic reference library within the workbench [[5]]. Early users and performance claims. Several research groups have already used Claude Science in pilot programs. Allen Institute neuroscientist Jérôme Lecoq said his team now has approximately 10 literature reviews exceeding 100 pages with agent-verified citations - work that previously took up to two years per review [[1]]. Stephen Francis, an epidemiologist at UCSF, reported the platform "dramatically accelerated the analysis, enabling comprehensive germline workups in roughly one-tenth the time it previously took" [[1]]. Manifold Bio, a biotech company, used Claude Science to assess surface expression, trafficking, and safety profiles for tissue-targeting drug candidates, ranking them against proprietary internal data [[1]]. Pharma industry positioning. The launch represents Anthropic's most significant push into the life-sciences vertical. Amodei framed Claude Science as having the potential to transform biology the way Claude Code reshaped programming over the past year [[2]]. Bristol Myers Squibb's presence at the event followed its May 20 announcement of a strategic agreement to deploy Claude Enterprise as a shared intelligence platform across its global operations, covering more than 30,000 employees in drug discovery, clinical development, manufacturing, and commercial functions [[4]]. Amodei referenced his October 2024 essay predicting that AI-enabled biology could compress 50 to 100 years of progress into 5 to 10, but tempered expectations at the event, saying he does not expect that outcome in the next couple of years and instead suggested it "might" happen a decade from now [[2]]. Competitive landscape. Claude Science enters a market where rivals are also targeting scientific research. OpenAI has developed GPT-Rosalind for scientific applications, while Google's Gemini and DeepMind's AlphaFold line continue to expand in structural biology and drug discovery [[5]]. Anthropic's approach differentiates by emphasizing workflow integration over model capability - the product does not claim to be a more capable model for biology, but rather a more useful environment for biologists. The auditable output history and local-infrastructure deployment address data-privacy concerns that have slowed AI adoption in pharmaceutical R&D [[1]] [[3]]. What's next. Claude Science is available immediately in beta for existing Claude Pro, Max, Team, and Enterprise subscribers. The AI for Science grant program will accept applications through July 15, 2026, with award notifications by July 31 and funded projects running from September 1 through December 1 [[1]]. Modal is contributing up to $2,000 in additional compute credits per grant project. The grant program targets academic and nonprofit research labs working in molecular epidemiology, single-cell sequencing, protein folding, CRISPR design, and related fields [[1]]. Discover more Stock market tracking Stocks & Bonds Company News